Cabotegravir/rilpivirine - Revision history

Aidan at 18:55, 2 July 2024

2024-07-02T18:55:16Z

← Older revision		Revision as of 18:55, 2 July 2024
Line 6:		Line 6:
	** Can be given ±1 week of target date		** Can be given ±1 week of target date
	** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything)		** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything)

	* Injections		* Injections
	** May need long needle to reach muscle in obese patients		** May need long needle to reach muscle in obese patients
	** Often given as [[rilpivirine]] into right buttock (R in R) and cabotegravir into left		** Often given as [[rilpivirine]] into right buttock (R in R) and [[cabotegravir]] into left
	* Virologic failures		* Virologic failures
	** Occur despite perfect adherence		** Occur despite perfect adherence
	** Increased if [[rilpivirine]] RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI		** Increased if [[rilpivirine]] RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI
	* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and [[hepatitis B coinfection		* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and [[HIV-hepatitis B coinfection]]
	** Use with caution if risk factors for virologic failure; may warrant closer monitoring		** Use with caution if risk factors for virologic failure; may warrant closer monitoring

Aidan at 18:53, 2 July 2024

2024-07-02T18:53:05Z

← Older revision		Revision as of 18:53, 2 July 2024
Line 9:		Line 9:
	* Injections		* Injections
	** May need long needle to reach muscle in obese patients		** May need long needle to reach muscle in obese patients
	** Often given as [[~~Rilpivirine\|<u>r</u>ilpivirine~~]] into ~~<u>r</u>ight~~ buttock and cabotegravir into left		** Often given as [[rilpivirine]] into right buttock (R in R) and cabotegravir into left
	* Virologic failures		* Virologic failures
	** Occur despite perfect adherence		** Occur despite perfect adherence
	** Increased if [[rilpivirine]] RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI		** Increased if [[rilpivirine]] RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI
	* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and hepatitis B coinfection		* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and [[hepatitis B coinfection
	** Use with caution if risk factors for virologic failure; may warrant closer monitoring		** Use with caution if risk factors for virologic failure; may warrant closer monitoring

Aidan at 18:48, 2 July 2024

2024-07-02T18:48:29Z

Aidan: Created page with "* Long-acting injectable medication used to treat HIV * Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary * Dosing 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks Can be given ±1 week of target date If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything) * Injectio..."

2023-04-02T02:17:55Z

Created page with "* Long-acting injectable medication used to treat HIV * Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary * Dosing ** 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks ** 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks ** Can be given ±1 week of target date ** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything) * Injectio..."

New page

* Long-acting injectable medication used to treat [[HIV]]
* Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary
* Dosing
** 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks
** 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks
** Can be given ±1 week of target date
** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything)

* Injections
** May need long needle to reach muscle in obese patients
** Often given as <u>r</u>ilpivirine into <u>r</u>ight buttock and cabotegravir into left
* Virologic failures
** Occur despite perfect adherence
** Increased if rilpivirine RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI
* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and hepatitis B coinfection
** Use with caution if risk factors for virologic failure; may warrant closer monitoring

[[Category:HIV]]
[[Category:Medications]]

← Older revision		Revision as of 18:48, 2 July 2024
Line 2:		Line 2:
	* Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary		* Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary
	* Dosing		* Dosing
	** 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks		** '''Monthly:''' 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks
	** 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks		** '''Every 2 monthly:''' 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks
	** Can be given ±1 week of target date		** Can be given ±1 week of target date
	** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything)		** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything)
Line 9:		Line 9:
	* Injections		* Injections
	** May need long needle to reach muscle in obese patients		** May need long needle to reach muscle in obese patients
	** Often given as <u>r</u>ilpivirine into <u>r</u>ight buttock and cabotegravir into left		** Often given as [[Rilpivirine\|<u>r</u>ilpivirine]] into <u>r</u>ight buttock and cabotegravir into left
	* Virologic failures		* Virologic failures
	** Occur despite perfect adherence		** Occur despite perfect adherence
	** Increased if rilpivirine RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI		** Increased if [[rilpivirine]] RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI
	* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and hepatitis B coinfection		* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and hepatitis B coinfection
	** Use with caution if risk factors for virologic failure; may warrant closer monitoring		** Use with caution if risk factors for virologic failure; may warrant closer monitoring